SUZHOU, China, Feb. 26, 2026 /PRNewswire/ -- As a global leader in robotic end-effector solutions, Changingtek Robotics Technology (Suzhou) Co., Ltd. proudly unveils the world's first adaptive "X2" — left-right dexterous hand (LRD Hand). Powered by an innovative tendon-driven transmission system, X2 enables autonomous reconstruction between left-hand and right-hand configurations. This breakthrough achieves significant advancements in lightweight design, operational flexibility, and functional freedom, redefining performance standards for robotic dexterous hands.
X2 offers multiple core performance advantages. Each of its five fingers is independently controlled, allowing coordinated execution of complex manipulation tasks. Despite its lightweight structure, it achieves a maximum gripping force of 50 N per hand and up to 10 N fingertip force per finger, with a force control accuracy of ±0.1 N, balancing heavy-load handling with precision-level operations. Its rich degrees of freedom enable high-difficulty tasks such as insertion, extraction, and assembly in narrow or complex environments.
Integrated with a proprietary high-precision vision coordination system, X2 supports object recognition, positioning, and adaptive grasping, ensuring efficient deployment and flexible operation across dynamic applications.
X2 is widely applicable in aerospace, intelligent manufacturing, laboratory automation, and service robotics. By enhancing equipment utilization and environmental adaptability, it empowers industries with more flexible and intelligent automation solutions.
Changingtek Robotics focuses on the R&D, manufacturing, and integration of solutions of dexterous hands, robotic end effectors, and embodied intelligent robots. The company has established three core technology platforms: mechanical intelligence, perception intelligence, and drive-control intelligence. Its comprehensive "Changingtek Hand" product portfolio spans industrial parallel hands, collaborative hands, dexterous hands, and heavy-duty hands, covering payload capacities from a few grams to several hundred kilograms — meeting full-scenario requirements from precision assembly to heavy material handling.
Leveraging tactile-visual fusion and AI-powered intelligent control technologies, Changingtek Robotics delivers stable and efficient intelligent gripping solutions for aerospace, automotive manufacturing, smart logistics, and beyond. By addressing industry challenges such as high application costs, limited flexibility, and complex deployment, the company continues to drive innovation and large-scale adoption of robotic end-effector technologies worldwide.
For more information, please click: https://youtu.be/Ay3KCk7ZuWE
Contact information:
Changingtek Robotics Technology (Suzhou) Co., Ltd.
Tel: +86 512 5323 3370 / +86 158 7124 2390
WhatsApp: +86 158 7124 2390
Email: support@ctek.ltd / hannah@ctek.ltd
Web: www.changingtek.com
Address: Building 18, Zhihuigu Science and Technology Innovation Park, No. 99, Fuda Road, Taicang City, Jiangsu Province, China
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Changingtek Robotics Launches the World's First Adaptive "X2" Left-Right Dexterous Hand
|
LYON, France, Feb. 26, 2026 /PRNewswire/ -- Antibody therapies are changing the treatment of cancer, inflammatory diseases and infections. However, many promising drug candidates fail in clinical trials. A study in Science Immunology shows that genOway's genO-hFcγR mouse model enables more accurate prediction of therapeutic antibody efficacy and safety.
Why Antibody Therapies Fail in Late-Stage Testing
Antibody therapies work in part by binding to Fcγ receptors, proteins found on immune cells that control key immune functions such as antibody-mediated cell killing and inflammation. Since these receptors are different between species, human therapies tested in standard laboratory mice give unreliable efficacy results or miss potential safety risks. These discrepancies cause expensive late-stage failures and slow patient access to new therapies.
A New Mouse Model with Humanized Fcγ Receptors Set to Become a Gamechanger
A new study published in Science Immunology showed that an innovative mouse model developed by genOway, genO-hFcγR, helps scientists better predict the efficacy and safety of therapeutic antibodies in humans. The model allows scientists to rank different antibody candidates by how they are likely to perform, measure how effectively they target specific immune cells, and evaluate their potential to slow disease progression. This gives researchers key early insights to guide decisions and accelerate drug development.
Video on genO-hFcγR mice: https://www.youtube.com/watch?v=H7xO-xGJV8Q
Read the publication: https://www.science.org/doi/10.1126/sciimmunol.ady7328
A Complex Scientific Challenge Achieved Through International Collaboration
Due to the species-specific nature of Fcγ receptors, developing this model demanded multidisciplinary expertise in mouse genetics, antibody biology, and human immunology.
The achievement was made possible through an international consortium of leading biopharmaceutical partners, led by genOway, who combined their knowledge to co-develop and co-validate the genO-hFcγR mouse model. Consortium members included genOway (France), a company specializing in developing highly predictive preclinical models; argenx (Belgium), a pioneer in Fc-engineering and FcRn biology; Innate Pharma (France), a leader in natural killer cell-based immunotherapies; and Vir Biotechnology (USA), focused on the development of immunotherapies; among other members. The group collaborated with VIB-Ghent University (Belgium), a leading immunology institute, to publish the study in Science Immunology. In this study, scientists at VIB-Ghent University mapped Fc receptor expression and regulation to illustrate how the new mouse model could be used to better model human disease and coordinated the publication of the work.
A Unique Solution Available for the Scientific Community
The genO–hFcγR model builds on a previous mouse model developed in 2008 by genOway and its scientific partners, in which multiple FcγR genes were humanized. Since its launch to the scientific community in 2024, genO-hFcγR has been adopted to advance preclinical programs of biopharmaceutical companies and nonprofit organizations, including the Gates Foundation, as one of the foundation's global health research initiatives.
Read the Gates Foundation press release at https://www.genoway.com/news-events/genoway-gates-foundation-2025
About genOway
genOway is a biotechnology company that provides highly predictive preclinical models and solutions to biopharmaceutical companies, CROs and academic institutions to bridge the gap between preclinical findings and clinical success. More information at genoway.com.
Contact
Ana REZA
Marketing Communications Manager
reza@genoway.com
LYON, France, Feb. 26, 2026 /PRNewswire/ -- Antibody therapies are changing the treatment of cancer, inflammatory diseases and infections. However, many promising drug candidates fail in clinical trials. A study in Science Immunology shows that genOway's genO-hFcγR mouse model enables more accurate prediction of therapeutic antibody efficacy and safety.
Why Antibody Therapies Fail in Late-Stage Testing
Antibody therapies work in part by binding to Fcγ receptors, proteins found on immune cells that control key immune functions such as antibody-mediated cell killing and inflammation. Since these receptors are different between species, human therapies tested in standard laboratory mice give unreliable efficacy results or miss potential safety risks. These discrepancies cause expensive late-stage failures and slow patient access to new therapies.
A New Mouse Model with Humanized Fcγ Receptors Set to Become a Gamechanger
A new study published in Science Immunology showed that an innovative mouse model developed by genOway, genO-hFcγR, helps scientists better predict the efficacy and safety of therapeutic antibodies in humans. The model allows scientists to rank different antibody candidates by how they are likely to perform, measure how effectively they target specific immune cells, and evaluate their potential to slow disease progression. This gives researchers key early insights to guide decisions and accelerate drug development.
Video on genO-hFcγR mice: https://www.youtube.com/watch?v=H7xO-xGJV8Q
Read the publication: https://www.science.org/doi/10.1126/sciimmunol.ady7328
A Complex Scientific Challenge Achieved Through International Collaboration
Due to the species-specific nature of Fcγ receptors, developing this model demanded multidisciplinary expertise in mouse genetics, antibody biology, and human immunology.
The achievement was made possible through an international consortium of leading biopharmaceutical partners, led by genOway, who combined their knowledge to co-develop and co-validate the genO-hFcγR mouse model. Consortium members included genOway (France), a company specializing in developing highly predictive preclinical models; argenx (Belgium), a pioneer in Fc-engineering and FcRn biology; Innate Pharma (France), a leader in natural killer cell-based immunotherapies; and Vir Biotechnology (USA), focused on the development of immunotherapies; among other members. The group collaborated with VIB-Ghent University (Belgium), a leading immunology institute, to publish the study in Science Immunology. In this study, scientists at VIB-Ghent University mapped Fc receptor expression and regulation to illustrate how the new mouse model could be used to better model human disease and coordinated the publication of the work.
A Unique Solution Available for the Scientific Community
The genO–hFcγR model builds on a previous mouse model developed in 2008 by genOway and its scientific partners, in which multiple FcγR genes were humanized. Since its launch to the scientific community in 2024, genO-hFcγR has been adopted to advance preclinical programs of biopharmaceutical companies and nonprofit organizations, including the Gates Foundation, as one of the foundation's global health research initiatives.
Read the Gates Foundation press release at https://www.genoway.com/news-events/genoway-gates-foundation-2025
About genOway
genOway is a biotechnology company that provides highly predictive preclinical models and solutions to biopharmaceutical companies, CROs and academic institutions to bridge the gap between preclinical findings and clinical success. More information at genoway.com.
Contact
Ana REZA
Marketing Communications Manager
reza@genoway.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
genOway: Revolutionizing the Prediction of Antibody Therapies in Humans with Unique Mouse Model
genOway: Revolutionizing the Prediction of Antibody Therapies in Humans with Unique Mouse Model
